AP3551A - Antiviral therapy - Google Patents

Antiviral therapy

Info

Publication number
AP3551A
AP3551A AP2012006445A AP2012006445A AP3551A AP 3551 A AP3551 A AP 3551A AP 2012006445 A AP2012006445 A AP 2012006445A AP 2012006445 A AP2012006445 A AP 2012006445A AP 3551 A AP3551 A AP 3551A
Authority
AP
ARIPO
Prior art keywords
antiviral therapy
antiviral
therapy
Prior art date
Application number
AP2012006445A
Other languages
English (en)
Other versions
AP2012006445A0 (en
Inventor
Mark Richard Underwood
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of AP2012006445A0 publication Critical patent/AP2012006445A0/xx
Application granted granted Critical
Publication of AP3551A publication Critical patent/AP3551A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2012006445A 2010-01-27 2011-01-24 Antiviral therapy AP3551A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (2)

Publication Number Publication Date
AP2012006445A0 AP2012006445A0 (en) 2012-08-31
AP3551A true AP3551A (en) 2016-01-18

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006445A AP3551A (en) 2010-01-27 2011-01-24 Antiviral therapy

Country Status (45)

Country Link
US (13) US20120295898A1 (sr)
EP (6) EP3127542B1 (sr)
JP (9) JP2013518107A (sr)
KR (4) KR101883750B1 (sr)
CN (2) CN102791129B (sr)
AP (1) AP3551A (sr)
AU (1) AU2011209788C1 (sr)
BR (1) BR112012018670A2 (sr)
CA (4) CA3060290C (sr)
CL (1) CL2012002080A1 (sr)
CO (1) CO6602152A2 (sr)
CR (1) CR20120423A (sr)
CY (6) CY1116509T1 (sr)
DK (4) DK3127542T3 (sr)
DO (2) DOP2012000205A (sr)
EA (4) EA025176B1 (sr)
EC (1) ECSP12012106A (sr)
ES (4) ES2670811T3 (sr)
FI (2) FI3494972T3 (sr)
FR (2) FR18C1043I2 (sr)
HK (1) HK1250335A1 (sr)
HR (4) HRP20150770T1 (sr)
HU (6) HUE065569T2 (sr)
IL (5) IL221007A (sr)
LT (5) LT3494972T (sr)
LU (1) LUC00090I2 (sr)
MA (1) MA34002B1 (sr)
ME (2) ME02182B (sr)
MX (4) MX2012008774A (sr)
MY (3) MY202778A (sr)
NO (2) NO2932970T3 (sr)
NZ (4) NZ627827A (sr)
PE (2) PE20121524A1 (sr)
PH (3) PH12012501537A1 (sr)
PL (4) PL3127542T3 (sr)
PT (4) PT2932970T (sr)
RS (4) RS54123B1 (sr)
SG (3) SG10201509476RA (sr)
SI (4) SI2531027T1 (sr)
SM (4) SMT201800594T1 (sr)
TN (1) TN2012000376A1 (sr)
TR (1) TR201807704T4 (sr)
UA (1) UA105556C2 (sr)
WO (1) WO2011094150A1 (sr)
ZA (1) ZA201205586B (sr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
MX364901B (es) 2012-10-23 2019-05-10 Cipla Ltd Composicion farmaceutica antirretroviral.
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
CA2897137A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (sr) 2013-07-12 2018-07-21
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
AU2014324829B2 (en) 2013-09-27 2017-09-07 Merck Sharp & Dohme Corp. Substituted Quinolizine Derivatives useful as HIV integrase inhibitors
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (sr) 2014-06-20 2018-06-23
US10189860B2 (en) 2014-07-29 2019-01-29 Lek Pharmaceuticals D.D. Hydrates of dolutegravir sodium
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017029225A1 (en) * 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20260015342A (ko) 2017-07-21 2026-02-02 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
US20200147092A1 (en) * 2017-07-21 2020-05-14 Viiv Healthcare Company Regimens for treating hiv infections and aids
CA3078624A1 (en) * 2017-10-13 2019-04-18 Viiv Healthcare Company Bi-layer pharmaceutical tablet formulation
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544961B1 (en) * 1996-06-25 2003-04-08 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
US20080076738A1 (en) * 2004-04-14 2008-03-27 Cai Zhenhong R Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
US20090318421A1 (en) * 2005-04-28 2009-12-24 Brian Alvin Johns Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
WO2001054625A1 (en) 2000-01-31 2001-08-02 Cook Biotech Incorporated Stent valves and uses of same
AU2002242926B2 (en) 2001-04-10 2007-10-11 Pfizer Inc. Pyrazole derivatives for treating HIV
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
KR20070002006A (ko) * 2004-02-11 2007-01-04 스미스클라인 비참 코포레이션 Ｈｉｖ 인테그라제 억제제
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
EP1758581A1 (en) * 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
US7534809B2 (en) 2004-09-17 2009-05-19 Idenix Pharmaceuticals, Inc. Phospho-indoles as HIV inhibitors
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20090093454A1 (en) 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
WO2006129134A1 (en) 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
AP2702A (en) * 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
RS52821B2 (sr) * 2006-01-20 2021-07-30 Janssen Sciences Ireland Unlimited Co Dugotrajno tretiranje hiv-infekcije sa tcm278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CA2657936C (en) 2006-07-21 2017-01-10 Gilead Sciences, Inc. Antiviral protease inhibitors
EA016267B1 (ru) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
EA200971115A1 (ru) 2007-06-29 2010-04-30 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новые ингибиторы обратной транскриптазы вич
TWI448457B (zh) 2007-07-06 2014-08-11 Gilead Sciences Inc 治療劑的藥物動力學性質之調節劑
CA2693044C (en) * 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
EP2217573A4 (en) 2007-11-01 2011-08-31 Uab Research Foundation TREATMENT AND PREVENTION OF VIRUS INFECTIONS
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
JP2011508747A (ja) 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のｃ−２１ケトルパン誘導体、それらの調製および使用
EP2250185A4 (en) * 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
ES2555209T3 (es) 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
EP2376453B1 (en) 2008-12-11 2019-11-20 VIIV Healthcare Company Intermediates for carbamoylpyridone hiv integrase inhibitors
MX351942B (es) 2008-12-11 2017-11-03 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
RS54123B1 (sr) 2010-01-27 2015-12-31 Viiv Healthcare Company Terapeutska kombinacija koja sadrži dolutegravir, abacavir i lamivudine
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
JP2013541493A (ja) 2010-06-17 2013-11-14 フュジアンス バイオメディカルズ インコーポレイテッド 抗ウイルス剤として有用な化合物、組成物、及び使用の方法
BR112013025368A8 (pt) 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544961B1 (en) * 1996-06-25 2003-04-08 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
US20060084627A1 (en) * 2002-06-27 2006-04-20 Medivir Ab Synergistic interaction of abacavir and alovudine
US20080076738A1 (en) * 2004-04-14 2008-03-27 Cai Zhenhong R Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds
US20090318421A1 (en) * 2005-04-28 2009-12-24 Brian Alvin Johns Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SONG I ET AL: "The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects", INTERNET CITATION, 12 September 2009 (2009-09-12), XP002697436 *

Also Published As

Publication number Publication date
DK3494972T3 (da) 2024-01-29
HRP20181531T1 (hr) 2018-11-16
EA037601B1 (ru) 2021-04-20
KR20170078868A (ko) 2017-07-07
PT3127542T (pt) 2018-11-26
IL281959A (en) 2021-05-31
KR20180078358A (ko) 2018-07-09
JP2023085431A (ja) 2023-06-20
JP2022071126A (ja) 2022-05-13
SG10201509476RA (en) 2015-12-30
HK1179522A1 (en) 2013-10-04
CY2024017I2 (el) 2025-05-09
US20160199379A1 (en) 2016-07-14
US20150238496A1 (en) 2015-08-27
EA202190473A3 (ru) 2021-12-31
JP2017008087A (ja) 2017-01-12
EP2531027A4 (en) 2013-07-03
HUE040554T2 (hu) 2019-03-28
US20180098992A1 (en) 2018-04-12
US20170119777A1 (en) 2017-05-04
PH12012501537A1 (en) 2018-02-07
MY207233A (en) 2025-02-07
EP4316599A3 (en) 2024-04-10
SI3494972T1 (sl) 2024-03-29
DK2531027T3 (en) 2015-07-20
KR101830715B1 (ko) 2018-04-04
CY2018029I1 (el) 2019-07-10
CN102791129B (zh) 2015-09-30
NZ627827A (en) 2016-02-26
TR201807704T4 (tr) 2018-06-21
CN102791129A (zh) 2012-11-21
PT2531027E (pt) 2015-09-16
RS54123B1 (sr) 2015-12-31
US11234985B2 (en) 2022-02-01
US20210401850A1 (en) 2021-12-30
EA201690872A2 (ru) 2016-08-31
JP2016145204A (ja) 2016-08-12
JP2018127473A (ja) 2018-08-16
SMT201800594T1 (it) 2019-01-11
NZ601319A (en) 2014-08-29
LT2932970T (lt) 2018-06-25
ECSP12012106A (es) 2013-05-31
MX356891B (es) 2018-06-19
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
EA202190473A2 (ru) 2021-06-30
PT3494972T (pt) 2024-02-12
LTPA2018013I1 (lt) 2018-11-12
CA2967453A1 (en) 2011-08-04
MY188334A (en) 2021-11-30
CY2024017I1 (el) 2025-05-09
IL245182A0 (en) 2016-06-30
US20120295898A1 (en) 2012-11-22
MX367938B (es) 2019-09-12
CA3003988C (en) 2020-01-07
PE20121524A1 (es) 2012-12-03
AU2011209788B2 (en) 2014-02-06
PH12016500195A1 (en) 2016-12-05
KR20120128640A (ko) 2012-11-27
HK1209629A1 (en) 2016-04-08
PH12018502489A1 (en) 2020-06-15
EP4316599A2 (en) 2024-02-07
CY1121040T1 (el) 2019-12-11
MX2012008774A (es) 2012-08-17
SMT201500177B (it) 2015-09-07
WO2011094150A1 (en) 2011-08-04
HUE026849T2 (en) 2016-08-29
US20170079982A1 (en) 2017-03-23
JP2013518107A (ja) 2013-05-20
LT3494972T (lt) 2024-03-12
CY2018029I2 (el) 2019-07-10
KR101883750B1 (ko) 2018-07-31
KR20160111536A (ko) 2016-09-26
US10426780B2 (en) 2019-10-01
CR20120423A (es) 2012-11-22
FR24C1024I2 (fr) 2025-06-27
DOP2012000205A (es) 2012-10-15
RS65183B1 (sr) 2024-03-29
BR112012018670A2 (pt) 2018-02-06
LTC3494972I2 (sr) 2025-11-10
EA032868B1 (ru) 2019-07-31
SI3127542T1 (sl) 2018-11-30
SMT202400063T1 (it) 2024-03-13
IL267658B (en) 2021-04-29
FR18C1043I1 (sr) 2018-11-30
PT2932970T (pt) 2018-06-08
US20200230147A1 (en) 2020-07-23
MX367937B (es) 2019-09-12
MY202778A (en) 2024-05-21
NO2018036I1 (no) 2018-10-15
CA2787691A1 (en) 2011-08-04
ME03058B (me) 2019-01-20
DK3127542T3 (en) 2018-11-12
HUE037812T2 (hu) 2018-09-28
NO2932970T3 (sr) 2018-08-18
EP2932970A1 (en) 2015-10-21
IL245182B (en) 2018-04-30
AU2011209788C1 (en) 2014-08-28
EP3494972A1 (en) 2019-06-12
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
NZ627826A (en) 2016-01-29
PL2531027T3 (pl) 2016-01-29
PL2932970T3 (pl) 2018-08-31
HUS1800042I1 (hu) 2018-11-28
CA3060290A1 (en) 2011-08-04
DOP2021000147A (es) 2022-01-16
RS57728B1 (sr) 2018-12-31
NZ627824A (en) 2016-02-26
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
JP2021091705A (ja) 2021-06-17
HUS2400017I1 (hu) 2024-06-28
ES2688925T3 (es) 2018-11-07
PL3494972T3 (pl) 2024-05-27
ES2969969T3 (es) 2024-05-23
EP3127542B1 (en) 2018-08-22
US20180200254A1 (en) 2018-07-19
EA201290583A1 (ru) 2013-04-30
EA201892277A1 (ru) 2019-03-29
DK2932970T3 (en) 2018-05-28
UA105556C2 (uk) 2014-05-26
JP6268386B2 (ja) 2018-01-31
PL3127542T3 (pl) 2019-03-29
US20170216284A1 (en) 2017-08-03
CA3003988A1 (en) 2011-08-04
EP2932970B1 (en) 2018-03-21
AU2011209788A1 (en) 2012-08-16
CY1116509T1 (el) 2017-03-15
HRP20180855T1 (hr) 2018-06-29
MA34002B1 (fr) 2013-02-01
CO6602152A2 (es) 2013-01-18
HK1250335A1 (en) 2018-12-14
EP3494972B1 (en) 2023-12-13
JP2019167371A (ja) 2019-10-03
EP3351249A1 (en) 2018-07-25
EA025176B1 (ru) 2016-11-30
HRP20150770T1 (hr) 2015-08-28
FR18C1043I2 (fr) 2019-10-11
SG10201707183TA (en) 2017-10-30
ES2543066T3 (es) 2015-08-14
EP3127542A1 (en) 2017-02-08
ME02182B (me) 2015-10-20
EP2531027A1 (en) 2012-12-12
IL257267A (en) 2018-03-29
AP2012006445A0 (en) 2012-08-31
SMT201800290T1 (it) 2018-07-17
JP2025131664A (ja) 2025-09-09
CA2967453C (en) 2018-07-17
LUC00090I2 (sr) 2019-01-08
US20170281636A1 (en) 2017-10-05
EP2531027B1 (en) 2015-05-06
ES2670811T3 (es) 2018-06-01
FI3494972T3 (fi) 2024-03-01
CA3060290C (en) 2022-07-12
IL281959B (en) 2021-12-01
IL267658A (en) 2019-08-29
HUE065569T2 (hu) 2024-06-28
CY1120457T1 (el) 2019-07-10
IL221007A0 (en) 2012-09-24
JP7724619B2 (ja) 2025-08-18
US20160339033A1 (en) 2016-11-24
CY1126771T1 (el) 2025-05-09
LTC2932970I2 (lt) 2022-04-25
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
PH12016500195B1 (en) 2021-08-04
LT3127542T (lt) 2018-11-26
CN105311033A (zh) 2016-02-10
SI2531027T1 (sl) 2015-08-31
TN2012000376A1 (en) 2014-01-30
CA2787691C (en) 2018-07-17
FIC20240016I1 (fi) 2024-05-31
SI2932970T1 (en) 2018-07-31
EA201690872A3 (ru) 2016-12-30
CN105311033B (zh) 2019-05-07
LTPA2024516I1 (sr) 2024-06-25
KR101964923B1 (ko) 2019-04-02
US20250017939A1 (en) 2025-01-16
CL2012002080A1 (es) 2012-11-30

Similar Documents

Publication Publication Date Title
HUS1800042I1 (hu) Antivirális terápia
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
IL226346A0 (en) Antiviral compounds
ZA201305897B (en) Combination therapy
ZA201400120B (en) Combination therapy
EP2585073A4 (en) ANTIVIRAL COMPOUNDS
EP2701744A4 (en) COMBINATION THERAPY
GB201005394D0 (en) Therapy
GB0905485D0 (en) Antiviral therapy
GB201016864D0 (en) Therapeutic methods
EP2629766A4 (en) COMBINATION THERAPY
ZA201207199B (en) Immune therapy
GB0908952D0 (en) Antiviral therapy
GB201004674D0 (en) Novel therapy
GB201021708D0 (en) Novel Therapeutic use
GB201114226D0 (en) Combination therapy
GB201018496D0 (en) Oro-tracheal defibrillator